NDC 63759-3032-01 - Bortezomib
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63759-3032
- Requested NDC
- 63759-3032-01
- Package NDCs from labels
- 63759-3032-1, 63759-3032-01
- Manufacturer
- Shilpa Medicare Limited | Amneal Oncology Private Limited
- Effective date
- 2024-08-30
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Bortezomib - Shilpa Medicare Limited | Amneal Oncology Private Limited | Shilpa Medicare Limited | Amneal Oncology Private Limited | 2024-08-30 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63759-3032-1 | Bortezomib | 1 in 1 CARTON | INJECTION | 1 | 1 | |
| 63759-3032-1 | Bortezomib | 1.4 mL in 1 VIAL, SINGLE-DOSE | INJECTION | 1.4 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63759-3032 | BORTEZOMIB INJECTION [SHILPA MEDICARE LIMITED] | 1 | Current NDC, 2 package rows | 20240926_61539d49-dc21-4576-8813-4bc8abf3868c.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BORTEZOMIB | BORTEZOMIB | Apotex Corp | b605b541-4bfd-db3e-9710-11c27f6dee6c | 2026-09-09 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Avenacy, LLC | decb5d94-2ea2-48d8-b08b-3196b24c0ed3 | 2026-01-09 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Gland Pharma Limited | cd698074-da21-4b53-8f6b-241535a8d598 | 2026-01-08 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Ningbo Shuangcheng Pharmaceutical Co., Ltd. | b17ca681-59a5-4af7-98a4-953b38379893 | 2025-12-30 | Warnings, Adverse reactions | 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Eugia US LLC | ed526447-a4fe-403b-8f08-21ce1b2fa8b7 | 2025-12-23 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | BluePoint Laboratories | 10f60367-0476-4acd-861b-90c18d4b8164 | 2025-11-20 | Warnings, Adverse reactions | 69G8BD63PP |
| VELCADE | BORTEZOMIB | Takeda Pharmaceuticals America, Inc. | 1521d321-e724-4ffc-adad-34bf4f44fac7 | 2025-08-28 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | BluePoint Laboratories | c6b620c6-f3d6-4ff3-b46a-50a66e6d41dd | 2025-07-31 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Meitheal Pharmaceuticals Inc. | 322e315f-dd94-475f-94f4-4d86a7eb5590 | 2025-07-23 | Warnings, Adverse reactions | 69G8BD63PP |
| BORUZU | BORTEZOMIB | Amneal Pharmaceuticals LLC | b92628dd-fa09-4c3a-b6a3-66426025807c | 2025-07-05 | Warnings, Adverse reactions | NDA212782 2608948 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Somerset Therapeutics LLC | dc737d3d-2a4e-448a-ad70-e013065c411c | 2025-05-10 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | NorthStar RxLLC | 3f02670b-5683-780c-9d38-5d8f0ef43a14 | 2025-05-06 | Warnings, Adverse reactions | 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Sagent Pharmaceuticals | 945fbaf0-7a79-4676-aa90-e9a213c0654f | 2025-05-05 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Fresenius Kabi USA, LLC | 3494c357-a692-4e55-89e1-93532b0baef7 | 2025-03-27 | Warnings, Adverse reactions | 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Zydus Pharmaceuticals USA Inc. | 0eb8daef-18da-43bb-b7c6-38c4c8b5dd80 | 2024-12-05 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Shilpa Medicare Limited | 61539d49-dc21-4576-8813-4bc8abf3868c | 2024-08-30 | Warnings, Adverse reactions | NDA212782 63759-3032-1 63759-3032 63759303201 2608948 71ebcbb5-31e2-4394-8a38-d833fd3c733a 61539d49-dc21-4576-8813-4bc8abf3868c 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Camber Pharmaceuticals, Inc. | 04aafa6a-a50d-4a47-a831-be8e8bb992ac | 2024-07-22 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Dr.Reddy's Laboratories, Inc. | 664bee24-7af2-2099-ac99-5dd71a1e5a14 | 2024-05-17 | Warnings, Adverse reactions | 69G8BD63PP |
| Bortezomib | BORTEZOMIB | Hospira, Inc. | 41e3de39-8278-4a75-badf-601e4602080d | 2024-04-09 | Warnings, Adverse reactions | 69G8BD63PP |
| BORTEZOMIB | BORTEZOMIB | Eugia US LLC | 76c7c3a5-fd2f-403f-85fd-65a64538eee7 | 2023-10-20 | Warnings, Adverse reactions | 69G8BD63PP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.